In advanced pancreatic cancer patients, GEM therapy may decrease memory T-cells, promote naive T-cell activation (91), and induce the proliferation of CD14+ monocytes and CD11c+ DC (92). This evidence concerns the gene CD14 and pancreatic neoplasm.